ArticleJournal of medical case reports2026
Application of microdeletion and microduplication screening in preimplantation genetic testing: a case report.
Article in Journal of medical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicrodeletions and microduplications are chromosomal variants ranging up to 3 Mb in size. These abnormalities often arise spontaneously and have significant clinical implications, including developmental delay and congenital anomalies. Given the resolution of conventional preimplantation genetic testing for aneuploidy is > 5-10 Mb, these clinically significant abnormalities are missed. This study presents two cases where preimplantation genetic testing-whole genome sequencing successfully identified small, clinically significant abnormalities. CASE PRESENTATION: In the first case, a couple undergoing in vitro fertilization opted to pursue preimplantation genetic testing-whole genome sequencing. Both the female patient (of East Asian ancestry, 32 years old) and the male patient (of European ancestry, 31 years old) did not disclose any history of genetic conditions. A screen of 50 pathogenic microdeletion and microduplication regions was performed in trophectoderm biopsies, identifying a 1.7-Mb microduplication at Xp22.31, linked to seizures, across multiple samples. The female patient later revealed a history of seizures, previously unaware of a genetic cause, highlighting the clinical relevance of this finding. In the second case, a couple of South Asian ancestry (34-year-old female and 36-year-old male) opted to pursue preimplantation genetic testing-whole genome sequencing for targeted screening of a 412-kb duplication on chromosome 10. Since the duplication had originated de novo in the male patient, the patient lacked informative family members for traditional preimplantation genetic testing probe development and was rejected by other preimplantation genetic testing laboratories. However, preimplantation genetic testing-whole genome sequencing successfully accommodated this region, enabling the identification of unaffected embryos.
conclusionPreimplantation genetic testing-whole genome sequencing offers higher chromosomal resolution than conventional preimplantation genetic testing, enabling general microdeletion/duplication screening as well as the detection of difficult chromosomal variations. Patients undergoing in vitro fertilization now have the option to screen for additional clinically relevant conditions and explore family planning solutions for familial complex chromosomal abnormalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.